MitraClip

Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives

Retrieved on: 
Tuesday, April 2, 2024
Moses Austin, Ohio State University, Edwards Lifesciences, Education, Patient, Global strategy, SVP, Coronary thrombosis, Business development, Radiology, University, Doctors Hospital, Faculty, Senior, Abstract, MD Anderson Cancer Center, Hospital, MitraClip, Baptist Hospital, Interventional radiology, Health, Global marketing

IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S.

Key Points: 
  • IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S.
  • Dr. Niekamp will be instrumental in advancing Inari’s mission to improve patient care through physician education and new device development.
  • Mr. Benner joins Inari with more than 16 years of senior leadership experience with high-growth and transformational medical technology companies.
  • We are honored to add his talents to our Medical Affairs team,” said Dr. Thomas Tu, Chief Medical Officer of Inari.

Abbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Retrieved on: 
Tuesday, April 2, 2024
Disease, Atrial fibrillation, Risk, Anatomy, Patient, Aortic stenosis, Endoclip, Tricuspid regurgitation, Structural heart disease, Death, Tricuspid valve, Abbott Northwestern Hospital, Quality of life, Heart failure, Leg, Heart, MitraClip, Safety, Fatigue, Blood, FDA, Physician, Food, Pharmaceutical industry

The tricuspid valve controls blood as it flows from the heart's right atrium to the right ventricle.

Key Points: 
  • The tricuspid valve controls blood as it flows from the heart's right atrium to the right ventricle.
  • TR occurs when the valve doesn't close properly, causing a leak and allowing blood to flow backward in the heart.
  • TR can force the heart to work harder, causing debilitating symptoms such as fatigue and shortness of breath.
  • TriClip has been approved for use in more than 50 countries, including in Europe and Canada, since its initial CE Mark approval in 2020.

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

Retrieved on: 
Tuesday, October 24, 2023
NYHA, MitraClip, Tricuspid regurgitation, NYSE, Health, MR, TR, Self-assessment, Mortality, Icahn School of Medicine at Mount Sinai, Functional, Mount Sinai Health System, G4, Quality of life, Endoclip, Risk, Mount Sinai, Blood, Safety, TCT, Hospital, Patient, Mitral regurgitation, Heart failure, ACC, New York Heart Association Functional Classification, Dietary supplement, Medical imaging, Pharmaceutical industry, Nursing, Medical device, KCCQ

Leaky valves in people with MR and TR can reduce the amount of blood being pumped through the body and make the heart work harder than it should.

Key Points: 
  • Leaky valves in people with MR and TR can reduce the amount of blood being pumped through the body and make the heart work harder than it should.
  • As a result, MR and TR can lead to other cardiovascular issues as well as severely limit a person's quality of life.
  • "For more than two decades, Abbott has continued to evolve and expand its minimally invasive treatment options for mitral and tricuspid regurgitation.
  • TriClip is approved for use in more than 50 countries, including in Europe and Canada, and is an investigational device in the U.S.

Late-Breaking Data from Landmark COAPT™ Trial Show Long-Term Benefits of Abbott's MitraClip™ Device

Retrieved on: 
Sunday, March 5, 2023
MitraClip, Mitral valve, NYSE, Blood, Patient, MR, Mount Sinai Health System, Death, The New England Journal of Medicine, Medicine, Heart, Cardiology, Quality of life, German Hospital in Tirana, Mitral regurgitation, Risk, Survival, Policy, FDA, American College, American College of Cardiology, Heart failure, Medical imaging, Pharmaceutical industry

The results were presented at the American College of Cardiology's 72nd Annual Scientific Session together with World Congress of Cardiology (ACC.23/WCC) held in New Orleans (March 4-6, 2023).

Key Points: 
  • The results were presented at the American College of Cardiology's 72nd Annual Scientific Session together with World Congress of Cardiology (ACC.23/WCC) held in New Orleans (March 4-6, 2023).
  • These data were simultaneously published in The New England Journal of Medicine .
  • Prior to MitraClip, most heart failure patients with clinically significant secondary MR were treated with medication only.
  • Patients in the COAPT trial received the first-generation MitraClip, the world's first transcatheter edge-to-edge repair (TEER) device.

Abbott's FreeStyle Libre® is Named Best Medical Technology in Last 50 Years by the Galien Foundation

Retrieved on: 
Friday, October 28, 2022
Prenatal nutrition, Diabetes, Continuous glucose monitor, Safety, Life, FreeStyle, Paganini Competition, Technology, Research, MitraClip, Nobel Prize, Film, Pharmaceutical industry, Medical device

The FreeStyle Libre system was awarded the 2019 Prix Galien USA Award for Best Medical Technology.

Key Points: 
  • The FreeStyle Libre system was awarded the 2019 Prix Galien USA Award for Best Medical Technology.
  • "The Prix Galien Golden Jubilee Awards honor the global 'best of the best' innovations that have improved the human condition over the last 50 years," said Bruno Cohen, Chairman of the Galien Foundation.
  • Over the years, Abbott has received 11 Prix Galien Awards for its innovations in pharmaceuticals and medical technology, including for Humira, MitraClipand FreeStyle Libre.
  • FreeStyle Libre 2 and FreeStyle Libre 3 systems:Failure to use FreeStyle Libre 2 or FreeStyle Libre 3 systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury.

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL

Retrieved on: 
Saturday, September 17, 2022
Linda, Safety, Edwards Lifesciences, Quality of life, Alfieri, Critical care, U.S. Securities and Exchange Commission, Ventricular remodeling, MitraClip, Significance, CLASP, Drug Quality and Security Act, Annual report, DMR, View, YouTube, PASCAL, NYSE, MD, Quality, CE marking, News, Forward-looking statement, Instagram, Edwards, Security (finance), Transcatheter arterial chemoembolization, Mitral valve, Risk, Securities Exchange Act of 1934, Adrenal insufficiency, Twitter, LinkedIn, Securities Act of 1933, Stroke, Structural heart disease, Randomized controlled trial, Multimedia, University, TCT, Pharmaceutical industry, Medical imaging, Medical device, Patient, Facebook

The study confirms TEER as a safe and effective therapy in patients with degenerative mitral regurgitation (DMR).

Key Points: 
  • The study confirms TEER as a safe and effective therapy in patients with degenerative mitral regurgitation (DMR).
  • The PASCAL system further demonstrated significant and sustained MR 1+ with 83.7 percent of patients at MR 1+ at six months.
  • The CLASP IID trial is a prospective randomized controlled trial comparing the safety and effectiveness of the PASCAL system to the MitraClip system.
  • Edwards, Edwards Lifesciences, the stylized E logo, CLASP, Edwards PASCAL, Edwards PASCAL Precision, PASCAL, and PASCAL Precision are trademarks of Edwards Lifesciences Corporation.

DGAP-News: SafeHeal Appoints Medical Device Industry Veteran Chris Richardson as Chief Executive Officer

Retrieved on: 
Monday, July 11, 2022
Venus, Quality of life, CEO, Colorectal cancer, Director, International, Large intestine, General manager, Sofinnova, Therapy, Colorectal surgery, Depression, Acquisition, SAFE, Patient, MD, Migraine, Board, MitraClip, Board of directors, Management, Medical imaging, Pharmaceutical industry, EU

PARIS, FRANCE and TAMPA, FL / ACCESSWIRE / July, 11, 2022 / SafeHeal , a leading innovator in the field of digestive surgery and developer of the Colovac device, announced today the appointment of Chris Richardson as Chief Executive Officer (CEO), who assumes responsibilities immediately.

Key Points: 
  • PARIS, FRANCE and TAMPA, FL / ACCESSWIRE / July, 11, 2022 / SafeHeal , a leading innovator in the field of digestive surgery and developer of the Colovac device, announced today the appointment of Chris Richardson as Chief Executive Officer (CEO), who assumes responsibilities immediately.
  • Richardson has over 30 years of experience in the medical device industry, and an extensive record of successfully taking medtech companies from startup to commercialization to acquisition.
  • Before that, Richardson was International President and Chief Commercial Officer of Direct Flow Medical, a transcatheter aortic valve company, and General Manager of Evalve (MitraClip), which was acquired by Abbott Vascular.
  • SafeHeal is an early-stage medical device company in Paris with US operations in Tampa, FL.

New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies

Retrieved on: 
Thursday, May 19, 2022
MitraClip, Parenteral nutrition, KCCQ, European Association for the Study of the Liver, Aortic stenosis, Cardiology, Patient, Woman, Quality of life, Health, Self-assessment, Association, Degenerative disease, LAA, Endoclip, TAVI, Adrenal insufficiency, Life, G4, NYSE, Functional, Man, University, Heart failure, NYHA, Frailty, PVL, Amulet, Classification, Morriston Hospital, M.D, New York Heart Association Functional Classification, Medical imaging, Medical device, Pharmaceutical industry, Online shopping

ABBOTT PARK, Ill., May 19, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced two late-breaking data presentations highlighting both TriClip, a first-of-its kind minimally invasive tricuspid heart valve repair device, and Navitor, the company's latest-generation transcatheter aortic valve implantation (TAVI) system.

Key Points: 
  • ABBOTT PARK, Ill., May 19, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced two late-breaking data presentations highlighting both TriClip, a first-of-its kind minimally invasive tricuspid heart valve repair device, and Navitor, the company's latest-generation transcatheter aortic valve implantation (TAVI) system.
  • The company also showcased new data for MitraClip and Amplatzer Amulet, two key components of the company's industry-leading structural heart portfolio.
  • "At Abbott, we're dedicated to delivering innovative technologies to help people with debilitating heart conditions live better lives through better health," said Michael Dale, senior vice president of Abbott's structural heart business.
  • The TriClip Transcatheter Tricuspid Valve Repair System and Navitor Transcatheter Aortic Valve are approved for investigational use only in the U.S.
    For U.S. important safety information on MitraClip, visit http://abbo.tt/MitraClipG4ISI .

New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies

Retrieved on: 
Thursday, May 19, 2022
MitraClip, Parenteral nutrition, KCCQ, European Association for the Study of the Liver, Aortic stenosis, Cardiology, Patient, Woman, Quality of life, Health, Self-assessment, Association, Degenerative disease, LAA, Endoclip, TAVI, Adrenal insufficiency, Life, G4, NYSE, Functional, Man, University, Heart failure, NYHA, Frailty, PVL, Amulet, Classification, Morriston Hospital, M.D, New York Heart Association Functional Classification, Medical imaging, Medical device, Pharmaceutical industry, Online shopping

ABBOTT PARK, Ill., May 19, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced two late-breaking data presentations highlighting both TriClip, a first-of-its kind minimally invasive tricuspid heart valve repair device, and Navitor, the company's latest-generation transcatheter aortic valve implantation (TAVI) system.

Key Points: 
  • ABBOTT PARK, Ill., May 19, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced two late-breaking data presentations highlighting both TriClip, a first-of-its kind minimally invasive tricuspid heart valve repair device, and Navitor, the company's latest-generation transcatheter aortic valve implantation (TAVI) system.
  • The company also showcased new data for MitraClip and Amplatzer Amulet, two key components of the company's industry-leading structural heart portfolio.
  • "At Abbott, we're dedicated to delivering innovative technologies to help people with debilitating heart conditions live better lives through better health," said Michael Dale, senior vice president of Abbott's structural heart business.
  • The TriClip Transcatheter Tricuspid Valve Repair System and Navitor Transcatheter Aortic Valve are approved for investigational use only in the U.S.
    For U.S. important safety information on MitraClip, visit http://abbo.tt/MitraClipG4ISI .

Saluda Medical Expands Executive Leadership Team with Vision for Growth

Retrieved on: 
Tuesday, November 16, 2021
Health, Compliance, Corporation, University, Intellectual property, GM, View, Business, Science, Spinal cord, Kellogg, Reading, General manager, MitraClip, Engineering, SCS, Boston Scientific, CEO, MBA, Cimpress, Senior, Chronic pain, Multimedia, Bruker, Corporate governance, Moses Austin, University of California, San Francisco, JD, Analog Devices, Government, Acquisition, Hyperreflexia, Horizon Fuel Cell Technologies, Company, LinkedIn, Harvard University, Evoke, Assistant, Marketing, Harvard Law School, Patient, General counsel, Brain, Pharmaceutical industry, Management

ARTARMON, Australia, Nov. 16, 2021 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical"), the pioneer in neuromodulation platform of closed-loop technologies designed to achieve unparalleled outcomes for patients suffering from neurological conditions, today announced the expansion of the Company's leadership team.

Key Points: 
  • ARTARMON, Australia, Nov. 16, 2021 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical"), the pioneer in neuromodulation platform of closed-loop technologies designed to achieve unparalleled outcomes for patients suffering from neurological conditions, today announced the expansion of the Company's leadership team.
  • He will initially target spinal cord stimulation for chronic pain and later expand into other neuromodulation platforms developed to address unmet patient needs.
  • Prior to Saluda, he was with Edwards Lifesciences for nearly a decade as the company delivered patient-centered, disruptive innovation and global market leadership.
  • Mr. Benner was on Edwards' Senior Leadership Team and held several senior roles in strategy, business development, marketing, and commercial operations throughout his career with Edwards.